Skip to Content

Softbank Is Investing $1.1 Billion to Help a Biotech Firm’s Tech Drive

August 9, 2017

The enormous technology conglomerate Softbank is continuing its spending spree, this time investing $1.1 billion into biotech firm Roivant Sciences. The drugmaker is currently developing seven neurological therapies and several treatments for rare diseases, among others. It’s the first time that Softbank has dipped into its $93 billion Vision Fund, which includes cash from Saudi Arabia, to support a drugmaker. Roivant’s CEO, Vivek Ramaswamy, tells Endpoints that the funding injection won’t all be used for regular biotech ideas: instead, some of it will be funnelled into what he calls “new technologies that can improve a biotech’s efficiency.”

Softbank is on a huge spending spree right now. In the past year, it has acquired the British chip designer ARM, invested $4 billion into chipmaker Nvidia, turned the London-based simulation startup Improbable into a unicorn, and gobbled up the robot maker Boston Dynamics. Next stop, drug tech.

Keep Reading

Most Popular

The inside story of how ChatGPT was built from the people who made it

Exclusive conversations that take us behind the scenes of a cultural phenomenon.

How Rust went from a side project to the world’s most-loved programming language

For decades, coders wrote critical systems in C and C++. Now they turn to Rust.

Design thinking was supposed to fix the world. Where did it go wrong?

An approach that promised to democratize design may have done the opposite.

Sam Altman invested $180 million into a company trying to delay death

Can anti-aging breakthroughs add 10 healthy years to the human life span? The CEO of OpenAI is paying to find out.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at with a list of newsletters you’d like to receive.